L3VLUP
ProSign in

BMY · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

BMYVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • BMY
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterBMYVRTX
Q3 202031 holders, $18.8bn31 holders, $21.9bn
Q4 202028 holders, $16.4bn30 holders, $18.4bn
Q1 202131 holders, $15.2bn31 holders, $15.4bn
Q2 202127 holders, $16.3bn30 holders, $12.7bn
Q3 202130 holders, $14.2bn35 holders, $10.1bn
Q4 202128 holders, $12.9bn28 holders, $12.4bn
Q1 202228 holders, $15.2bn23 holders, $16.1bn
Q2 202231 holders, $14.8bn25 holders, $18.1bn
Q3 202227 holders, $12.2bn22 holders, $18.4bn
Q4 202233 holders, $10.0bn28 holders, $18.4bn
Q1 202329 holders, $8.4bn26 holders, $21.4bn
Q2 202329 holders, $7.9bn27 holders, $24.7bn
Q3 202332 holders, $7.5bn33 holders, $24.3bn
Q4 202330 holders, $7.2bn32 holders, $28.6bn
Q1 202420 holders, $6.6bn31 holders, $29.8bn
Q2 202426 holders, $6.4bn29 holders, $33.4bn
Q3 202431 holders, $7.9bn27 holders, $33.5bn
Q4 202427 holders, $6.6bn26 holders, $28.5bn
Q1 202520 holders, $6.6bn21 holders, $35.4bn
Q2 202522 holders, $5.6bn21 holders, $32.3bn
Q3 202528 holders, $5.4bn22 holders, $25.9bn
Q4 202525 holders, $7.7bn26 holders, $31.8bn
Q1 202627 holders, $8.3bn25 holders, $31.8bn
Q2 202622 holders, $8.2bn26 holders, $34.6bn
BMY

Bristol-myers Squibb Co

Holders
28
Reported value
$5.4bn
Buyers
19
Sellers
9

Breadth +10 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
22
Reported value
$25.9bn
Buyers
13
Sellers
10

Breadth +3 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2025

Among the 37 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only BMY (15)

Acadian Asset Management LLC, AQR Capital Management LLC, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Dodge & Cox, Eisler Capital Management Ltd, GAMCO Investors Inc, Jane Street Group LLC, Marshall Wace LLP, Millennium Management LLC, Quantbot Technologies LP, Schonfeld Strategic Advisors LLC, Two Sigma Advisers LP, Two Sigma Investments LP, Verition Fund Management LLC

Only VRTX (9)

ARK Investment Management LLC, Baillie Gifford & Co, Capital Research Global Investors, Capital World Investors, Fidelity (FMR LLC), Freestone Grove Partners LP, Hudson Bay Capital Management LP, MFS Investment Management, Neuberger Berman Group LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →